Please find attached the outcome of the board meeting.

BSE Limited, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai - 400 001. Scrip code: 531207 Subject: Outcome of Board Meeting Ref: Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Dear Sir/Madam, Pursuant to Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations"), we wish to inform you that the Board of Directors of the Company at its meeting held today i.e., 13th August, 2026, has inter alia considered and approved the following matters: 1. Un-Audited Financial Results of the Company for the first quarter ended 30th June, 2026, together with all the Limited Review report for the first quarter ended 30th June, 2026 prepared in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, is attached herewith. 2. Corporate office and the place for maintaining and keeping the books of accounts of the company at 205, 2nd Floor, BLA Business Park, CTS No 492 A 1 to 4 and 492 B Near Altanta Center, Sonawala Lane Road Village Pahadi, Goregaon East, Mumbai 400063, Maharashtra. The meeting commenced at 12:30 p.m. and concluded at 01:00 p.m. Kindly take the same on record. For Cresanto Global Limited (Formerly known as Raymed Labs Limited) (Prashant Nathmal Bajaj) Managing Director DIN: 06634046 Date: 13th August, 2026 Place: Mumbai Corporate Office: 201, 2nd Floor, A wing, Corporate Avenue, Sonawala Lane, Goregaon East, Mumbai-400063 K TP& SCo. CHARTERED ACCOUNTANTS Limited Review Report on the Unaudited Quarterly and year-to-date Standalone Financial Results of Cresanto Global Limited (Formerly known as Raymed Labs Limited) under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended. The Board of Directors Cresanto Global Limited We have reviewed the accompanying statement of unaudited standalone Financial Results of Cresanto Global Limited (Formerly known as Raymed Labs Limited) (“the Company”) for the quarter ended 30% June 2026 (“the statement”). This statement is being submitted to the requirements of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended. (Listing Regulations) This Statement, which is the responsibility of the Company’s Management and approved by the Company’s Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 ‘Interim Financial Reporting’ (‘Ind AS 34’), prescribed under Section 133 of the Companies Act, 2013 (‘the Act’) read with relevant rules issued thereunder and other recognized accounting principles generally accepted in India and in compliance with the Regulations. Our responsibility is to express a conclusion on the Statement based on our review. We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, “Review of Interim Financial Information Performed by the Independent Auditor of the Entity” issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Act and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other recognized accounting principles generally accepted in India has not disclosed the information required to be disclosed in terms of the Regulations including the manner in which it is to be disclosed, or that it contains any material misstatement. For KT PS &Co. Chartered Accountants Firm’s Registration No. 134942W Anurag Khandelia CA Anurag Khandelia Partner Mem. No. 172909 UDIN: 26172909QIUKWN3121 Place: Mumbai Date: 13/08/2026 607, Corporate Annexe, Sonawala Lane, Goregaon East, Mumbai — 400 063, Maharashtra, India Phone: 022-16851128 | E-mail : info@ktps.co.in CRESANTO GLOBAL LIMTED (formerly known as Raymed Labs Limited) CIN: L22203UP1992PLC014240 STATEMENT OF UNAUDITED PROFIT AND LOSS FOR THE QUARTER ENDED JUNE 30, 2026 (INR in Lakhs) For the qtr ended For the qtr ended For the qtr ended For the Year ended Particulars Note No. June 30, 2026 March 31, 2026 June 30, 2025 March 31, 2026 I Revenue Revenue from Operations 22 - - - 5.39 Other Income 23 - 0.17 - 2.17 Total Income - 0.17 - 7.56 II Expenses Purchases of Stock in Trade - - - 5 .22 Change in Inventories of Finished Goods/Work-in-progress/ Stock in Trade 24 - - - - Employee Benefits Expenses 25 0.46 3.40 3.60 14.00 Finance Costs 26 - 15.86 0.01 15.86 Depreciation and Amortization Expenses 27 - - - - Other Expenses 28 5.42 4.44 5.60 15.50 Total Expenses 5.88 23.70 9.21 50.58 III Profit before tax (I- II) (5.88) (23.53) (9.21) (43.02) IV Less: Tax Expense: Current Tax Tax expenses of previous year 0 .01 0 .01 Deferred Tax - - - Total Tax Expense - 0 .01 - 0 .01 V Profit for the Year (III-IV) (5.88) (23.54) (9.21) (43.03) VI Other Comprehensive Income Items that will not be reclassified to profit or loss Re-measurement gains/ (losses) on defined benefit obligations Tax Effect on above Other Comprehensive Income for the year, net of tax - - - - VII Total Comprehensive Income for the year (V+VI) (Comprising (5.88) (23.54) (9.21) (43.03) Profit and Other Comprehensive Income for the year) VIIIEarnings Per Equity Share (Face Value INR 10 Per Share): 29 Basic and Diluted (INR) ( 0.14) ( 0.55) ( 0.22) ( 1.01) Summary of Significant 2-4 Accounting Policies The notes referred to above are an integral part of the financial statements For and on behalf of the Board of Directors Prashant Nathmal Bajaj Managing Director & CFO DIN- 06634046 Place: Mumbai Dated : 13th August, 2026 Corporate Office: 201, 2nd Floor, A wing, Corporate Avenue, Sonawala Lane, Goregaon East, Mumbai-400063